Latest news and press releases about NanoVibronix, Inc. (NAOV): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
NanoVibronix, Inc., operating through its subsidiary NanoVibronix Ltd., develops and commercializes innovative, non-invasive devices that stimulate biological responses for therapeutic purposes. Their core focus areas include mitigating biofilm formation, accelerating wound repair, and alleviating pain.
Price
| Price | $1.90 |
| Market Cap | $2M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.38 |
| EV / EBITDA | -2.96 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -54.29% |
| Return on Invested Capital | -65.14% |
| Return on Assets | -44.22% |
| Gross Margin | -26.06% |
| Operating Margin | -1362.72% |
| Net Margin | -1259.55% |
Related companies: ACON · AMIX · BBLG · BJDX · CNSP · GRI · HSCS
Explore sector: Healthcare · Medical - Devices
More sections of NAOV: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks